Terbinafine HCl 250 mg Tablet Formulations Under Non-Fasting Conditions
NCT00833664
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
22
Enrollment
INDUSTRY
Sponsor class
Conditions
Healthy
Interventions
DRUG:
Terbinafine HCl 250mg tablets
DRUG:
Lamisil® 250 mg Tablets
Sponsor
Teva Pharmaceuticals USA